Ra Capital Management, L.P. Buys 110,206 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) Director Ra Capital Management, L.P. acquired 110,206 shares of the stock in a transaction dated Friday, March 7th. The shares were bought at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the purchase, the director now directly owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. This trade represents a 1.10 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, March 5th, Ra Capital Management, L.P. acquired 341,742 shares of Janux Therapeutics stock. The stock was purchased at an average price of $30.64 per share, for a total transaction of $10,470,974.88.

Janux Therapeutics Stock Down 0.4 %

Janux Therapeutics stock traded down $0.11 during mid-day trading on Friday, hitting $30.64. 653,704 shares of the company were exchanged, compared to its average volume of 815,271. The company has a market capitalization of $1.81 billion, a PE ratio of -26.19 and a beta of 3.23. The business has a fifty day moving average of $41.74 and a 200 day moving average of $47.55. Janux Therapeutics, Inc. has a 1-year low of $29.63 and a 1-year high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Research analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Janux Therapeutics in a research note on Monday. Lifesci Capital raised shares of Janux Therapeutics to a “strong-buy” rating in a report on Friday, December 27th. BTIG Research lifted their price target on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Leerink Partners lifted their target price on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 3rd. Finally, Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $88.00.

Hedge Funds Weigh In On Janux Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. RA Capital Management L.P. increased its position in Janux Therapeutics by 13.1% in the fourth quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company’s stock worth $554,977,000 after buying an additional 1,200,000 shares during the last quarter. FMR LLC grew its holdings in shares of Janux Therapeutics by 10.8% during the fourth quarter. FMR LLC now owns 8,669,941 shares of the company’s stock worth $464,189,000 after purchasing an additional 845,266 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Janux Therapeutics by 41.2% in the fourth quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company’s stock worth $190,617,000 after purchasing an additional 1,038,996 shares during the last quarter. Paradigm Biocapital Advisors LP raised its stake in Janux Therapeutics by 46.5% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company’s stock valued at $188,246,000 after purchasing an additional 1,115,412 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its stake in Janux Therapeutics by 47.6% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company’s stock worth $163,926,000 after purchasing an additional 986,750 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.